<span item_type="fundamental" item_id="7f5b959585eb78b69bb42ae8bca4932a" counter_id="ST/US/CPMD" env="prod"></span><span item_type="announcement" item_id="582798662788186497" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 656.61 K.</p><p>EPS: As of FY2025 Q3, the actual value is USD 0.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -242.07 K.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>Revenue</strong>: For the three months ended September 30, 2025, revenue was $656,606, compared to $312,164 for the same period in 2024. For the nine months ended September 30, 2025, revenue was $1,223,533, compared to $338,003 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1081938/000165495425013083/canna_10q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Gross Loss</strong>: The gross loss for the three months ended September 30, 2025, was $440,000, compared to $356,158 in 2024. For the nine months ended September 30, 2025, the gross loss was $1,563,817, compared to $1,244,023 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1081938/000165495425013083/canna_10q.htm"></span></li><li><strong>Operating Expenses</strong>: Total operating expenses for the three months ended September 30, 2025, were $495,646, compared to $159,818 in 2024. For the nine months ended September 30, 2025, operating expenses were $890,394, compared to $859,064 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1081938/000165495425013083/canna_10q.htm"></span></li><li><strong>Net Loss</strong>: The net loss for the three months ended September 30, 2025, was $1,477,811, compared to a net income of $188,421 in 2024. For the nine months ended September 30, 2025, the net loss was $3,581,863, compared to $6,164,948 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1081938/000165495425013083/canna_10q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Cash Used in Operating Activities</strong>: For the nine months ended September 30, 2025, cash used in operating activities was $1,850,544, compared to $1,517,342 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1081938/000165495425013083/canna_10q.htm"></span></li><li><strong>Cash Provided by Financing Activities</strong>: For the nine months ended September 30, 2025, cash provided by financing activities was $1,849,315, compared to $1,523,691 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1081938/000165495425013083/canna_10q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Impairment of Inventory</strong>: Loss on impairment of inventory included in cost of goods sold was $1,506,292 for the nine months ended September 30, 2025, compared to $529,634 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1081938/000165495425013083/canna_10q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company plans to increase its growth capacity at the Facility to support sales of cannabis to European markets, focusing on Germany and Israel. This includes increasing operations from six to ten growing rooms over the next one to two years and opening a second drying and packing room.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1081938/000165495425013083/canna_10q.htm"></span></li><li><strong>Non-Core Business</strong>: The company is working on obtaining European Union Good Manufacturing Practices (EU-GMP) certification to reduce costs and shipping timelines by eliminating the need for a third-party European intermediary for packaging.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1081938/000165495425013083/canna_10q.htm"></span></li></ul>

CannaPharmaRX, Inc. | 10-Q: FY2025 Q3 Revenue: USD 656.61 K